机构:
Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA
Emory Eye Ctr, Emory Vis, Atlanta, GA 30342 USAEmory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA
Randleman, J. Bradley
[1
,2
]
Khandelwal, Sumitra S.
论文数: 0引用数: 0
h-index: 0
机构:
Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USAEmory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA
Khandelwal, Sumitra S.
[3
]
论文数: 引用数:
h-index:
机构:
Hafezi, Farhad
[4
,5
,6
,7
]
机构:
[1] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA
[2] Emory Eye Ctr, Emory Vis, Atlanta, GA 30342 USA
Since its inception in the late 1990s, corneal cross-linking has grown from an interesting concept to a primary treatment for corneal ectatic disease worldwide. Using a combination of ultraviolet-A light and a chromophore (vitamin B2, riboflavin), the cornea can be stiffened, usually with a single application, and progressive thinning diseases such as keratoconus arrested. Despite being in clinical use for many years, some of the underlying processes, such as the role of oxygen and the optimal treatment times, are still being worked out. More than a treatment technique, corneal cross-links represent a physiological principle of connective tissue, which may explain the enormous versatility of the method. We highlight the history of corneal cross-linking, the scientific underpinnings of current techniques, evolving clinical treatment parameters, and the use of cross-linking in combination with refractive surgery and for the treatment of infectious keratitis. (C) 2015 Elsevier Inc. All rights reserved.
机构:
Cornea Res Fdn Amer, 9002 N Meridian St,Suite 212, Indianapolis, IN 46260 USACornea Res Fdn Amer, 9002 N Meridian St,Suite 212, Indianapolis, IN 46260 USA
Price, Marianne O.
Price, Francis W., Jr.
论文数: 0引用数: 0
h-index: 0
机构:
Price Vis Grp, Indianapolis, IN USACornea Res Fdn Amer, 9002 N Meridian St,Suite 212, Indianapolis, IN 46260 USA